From his pronounced experience in preclinical research (Novartis & Roche), Konrad brings a broad expertise in small molecule-, peptide- and ASO/siRNA science, which allowed him to advance various molecules into clinical development (cardiometabolic & infectious diseases). He authored over 100 patents & publications. Being highly passionate about designed polypharmacology, Konrad joined SixPeaks Bio as Head of Therapeutic Modalities in 2023.
Konrad holds a PhD in Chemistry from the Eberhardt Karls University in Tübingen, Germany